StreetAlpha.app
Home › Stocks › PRME

Prime Medicine, Inc. (PRME)

Healthcare
$3.55
▼ −7.55%
LAST CLOSE · NOV 20

Prime Medicine is a Cambridge, Massachusetts biotechnology company developing gene editing medicines for genetic diseases. It last closed at $3.55 on Nov 20, down 7.55% on the day. The next earnings report for PRME is expected around Tue, Mar 2, 2027. For the quarter ended Sep 2026, PRME reported EPS of -$0.22 on revenue of $4.2M, with revenue up 243.9% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings.

AI Auto Pilots
Is PRME in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PRME.

Key Stats

Last 12 months
Results
Revenue
$7.1M
+18.1% vs a year ago
Net income
−$176.4M
−2497.6% margin
EPS (diluted)
−$0.97
Free cash flow
−$158.5M
−2245.3% margin
Valuation
Market cap
$645.8M
181.9M shares
P/E
–
No P/E while losing money
Price to sales
91.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$54.9M
At Sep 30
Shareholder equity
$8.4M
Shares outstanding
181.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $3.0M$3.0MFY2024FY2025: $4.6M$4.6MFY2025

From PRME's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · Time not announced
Reported EPS
-$0.22
Quarter ended Sep 2026
Year ago EPS
-$0.32
Same quarter last year
Revenue
$4.2M
+243.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.31Dec '24Mar 2025: -$0.40Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.32Sep '25Dec 2025: -$0.24Dec '25Mar 2026: -$0.28Mar '26Jun 2026: -$0.24Jun '26Sep 2026: -$0.22Sep '26Latest -$0.22
Revenue by quarter
Dec 2024: $2.2MDec '24Mar 2025: $1.5MMar '25Jun 2025: $1.1MJun '25Sep 2025: $1.2MSep '25Dec 2025: $838,000Dec '25Sep 2026: $4.2MSep '26Latest $4.2M
How PRME moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 10, 2026After the close+10.3%
Aug 6, 2026Time not announced−4.2%
May 7, 2026Time not announced−8.7%
Mar 3, 2026Time not announced−9.2%
Nov 7, 2025Time not announced−8.8%
Jul 30, 2025After the close−4.6%
May 8, 2025Time not announced−7.0%
Feb 28, 2025Time not announced+4.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PRMEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PRME
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PRME

Technical Analysis

PRME · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 21% below its 20 day and 5% below its 50 day average. It is 1% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the 200 day average at $3.51, and the nearest resistance the swing high (May 29) at $3.56.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 13.3%/day
Key levels
$5.9152 week high+66.5%
$4.3120 day average+21.4%
$3.83Pivot R1+7.9%
$3.7450 day average+5.4%
$3.66Pivot+3.1%
$3.56Swing high (May 29)+0.3%
$3.55100 day average+0.0%
$3.55Last close
$3.51200 day average−1.1%
$3.38Pivot S1−4.8%
$3.38Swing low (Oct 23)−4.8%
$2.6752 week low−24.8%
Indicators
RSI (14)43.28Middle of its rangeNeutral
MACD-0.02Below its signal lineBearish
Stochastic6.8Near the bottom of its rangeOversold
ADX (14)19.7No clear trend
Williams %R-96.3Oversold below −80, overbought above −20Oversold
CCI (20)-114.1Oversold below −100, overbought above 100Oversold
Rate of change−23.7%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for PRME

What happened before

See how PRME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PRME usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PRME has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PRMEHow many large options trades hit PRME, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PRME Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 79 selling
  • ▲Held by funds +9.7 pts
  • ●Funds holding +0
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1871870.0%
In funds' top 1000–
Held by funds68.3%58.6%+9.7 pts
New / increased25 / 6822 / 61+12.0%
Reduced / sold out55 / 2467 / 24−13.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRME institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PRME Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 1, 2025Alphabet Inc.10% ownerBuy1,500,000$3.30$5.0M
Aug 1, 2025Steven Gillis10% ownerBuy3,030,300$3.30$10.0M
Aug 1, 2025ARCH Venture Fund XII, L.P.10% ownerBuy3,030,300$3.30$10.0M
Aug 1, 2025Robert NelsenDirectorBuy3,030,300$3.30$10.0M
Jun 30, 2025David R. Liu10% ownerBuy21,000$2.52$53K
Jun 23, 2025David R. Liu10% ownerBuy21,000$2.16$45K
Every insider buy and sale for PRME over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PRME insider trades →

From SEC Form 4 filings by PRME's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRME is in one of them and how their past PRME trades turned out.

PRME in the AI portfolios
Loading…

PRME News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRME in an article yet. Here's the latest on the wider market.

PRME in the news

About Prime Medicine

Prime Medicine is a biotechnology company based in Cambridge, Massachusetts. It develops gene editing medicines built on a technology called Prime Editing, which is designed to rewrite specific sections of DNA without cutting both strands of the double helix. The company's programs target inherited diseases, with early focus on conditions affecting the liver and lungs and on certain blood disorders. Its medicines are intended for patients with these genetic conditions and the doctors who treat them.

Headquarters
Cambridge, MA